Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 ce11s

Molecular and Cellular Biology

Volumn 28, Issue 3, 2008, Pages 997-1006

  Reineke, Erin L ^a   Lam, Minh ^a,b   Liu, Qing ^a   Liu, Yu ^a   Stanya, Kristopher J ^a   Chang, Kun Sang ^c   Means, Anthony R ^d   Kao, Hung Ying ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; PEPTIDYLPROLYL ISOMERASE PIN1; PROMYELOCYTIC LEUKEMIA PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SENESCENCE; STEADY STATE; SUMOYLATION; VIRUS INFECTION;

AMINO ACID MOTIFS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PEPTIDYLPROLYL ISOMERASE; PHENOTYPE; PROTEIN BINDING; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 38549132438     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01848-07     Document Type: Article

References (56)

1. Bernardi, R., and P. P. Pandolfi. 2003. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22:9048-9057.
2. Borden, K. L. 2002. Pondering the promyelocyte leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell. Biol. 22:5259-5269.
3. Buschbeck, M., I. Uribesalgo, A. Ledl, A. Gutierrez, S. Minucci, S. Muller, and L. Di Croce. 2007. PML4 induces differentiation by Myc destabilization. Oncogene 26:3415-3422.
4. Chelbi-Alix, M. K., L. Pelicano, F. Quignon, M. H. Koken, L. Venturini, M. Stadler, J. Pavlovic, L. Degos, and H. de The. 1995. Induction of the PML protein by interferons in normal and APL cells. Leukemia 9:2027-2033.
5. Ching, R. W., G. Dellaire, C. H. Eskiw, and D. P. Bazett-Jones. 2005. PML bodies: a meeting place for genomic loci? J. Cell Sci. 118:847-854.
6. De Nicola, F., T. Bruno, S. Iezzi, M. Di Padova, A. Floridi, C. Passananti, G. Del Sal, and M. Fanciulli. 2007. The prolyl isomerase Pin1 affects Che-1 stability in response to apoptotic DNA damage. J. Biol. Chem. 282:19685-19691.
7. de Stanchina, E., E. Querido, M. Narita, R. V. Davuluri, P. P. Pandolfi, G. Ferbeyre, and S. W. Lowe. 2004. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13:523-535.
8. de The, H., C. Lavau, A. Marchio, C. Chomienne, L. Degos, and A. Dejean. 1991. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675-684.
9. Doucas, V., and R. M. Evans. 1996. The PML nuclear compartment and cancer. Biochim. Biophys. Acta 1288:M25-M29.
10. Dyck, J. A., G. G. Maul, W. H. Miller, Jr., J. D. Chen, A. Kakizuka, and R. M. Evans. 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333-343.
11. Everett, R. D., P. Lomonte, T. Sternsdorf, R. van Driel, and A. Orr. 1999. Cell cycle regulation of PML modification and ND10 composition. J. Cell Sci. 112:4581-4588.
12. Ferbeyre, G., E. de Stanchina, E. Querido, N. Baptiste, C. Prives, and S. W. Lowe. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14:2015-2027.
13. Galat, A. 2003. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity - targets - functions. Curr. Top. Med. Chem. 3:1315-1347.
14. Gurrieri, C., P. Capodieci, R. Bernardi, P. P. Scaglioni, K. Nafa, L. J. Rush, D. A. Verbel, C. Cordon-Cardo, and P. P. Pandolfi. 2004. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 96:269-279.
15. Hamdane, M., C. Smet, A. V. Sambo, A. Leroy, J. M. Wieruszeski, P. Delobel, C. A. Maurage, A. Ghestem, R. Wintjens, S. Begard, N. Sergeant, A. Delacourte, D. Horvath, I. Landrieu, G. Lippens, and L. Buee. 2002. Pin1: a therapeutic target in Alzheimer neurodegeneration. J. Mol. Neurosci. 19:275-287.
16. Hayakawa, F., and M. L. Privalsky. 2004. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5:389-401.
17. Hofmann, T. G., and H. Will. 2003. Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ. 10:1290-1299.
18. Ishov, A. M., A. G. Sotnikov, D. Negorev, O. V. Vladimirova, N. Neff, T. Kamitani, E. T. Yeh, J. F. Strauss, 3rd, and G. G. Maul. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:221-234.
19. Jensen, K., C. Shiels, and P. S. Freemont. 2001. PML protein isoforms and the RBCOTRIM motif. Oncogene 20:7223-7233.
20. Joseph, J. D., E. S. Yeh, K. I. Swenson, A. R. Means, and Winkler. 2003. The peptidyl-prolyl isomerase Pin1. Prog. Cell Cycle Res. 5:477-487.
21. Kakizuka, A., W. H. Miller, Jr., K. Umesono, R. P. Warrell, Jr., S. R. Frankel, V. V. Murty, E. Dmitrovsky, and R. M. Evans. 1991. Chromosomal translocation t(15;17) in human acute promyelocyte leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663-674.
22. Kawai, T., S. Akira, and J. C. Reed. 2003. ZIP kinase triggers apoptosis from nuclear PML oncogenic domains. Mol. Cell. Biol. 23:6174-6186.
23. 3-indueed PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193:1361-1371.
24. Lavau, C., A. Marchio, M. Fagioli, J. Jansen, B. Falini, P. Lebon, F. Grosveld, P. P. Pandolfi, P. G. Pelicci, and A. Dejean. 1995. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 11:871-876.
25. Lavoie, S. B., A. L. Albert, and M. Vincent. 2003. Unexpected roles of the peptidyl-prolyl cis/trans isomerase Pin1. Med. Sci. (Paris) 19:1251-1258. [In French.]
26. Le, X. F., S. Vallian, Z. M. Mu, M. C. Hung, and K. S. Chang. 1998. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene 16:1839-1849.
27. Lu, P. J., X. Z. Zhou, M. Shen, and K. P. Lu. 1999. Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science 283:1325-1328.
28. Mann, K. K., and W. H. Miller, Jr. 2004. Death by arsenic: implications of PML sumoylation. Cancer Cell 5:307-309.
29. Maul, G. G., D. Negorev, P. Bell, and A. M. Ishov. 2000. Review: properties and assembly mechanisms of ND10, PML bodies, or PODs. J. Struct. Biol. 129:278-287.
30. Melnick, A., and J. D. Licht. 1999. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215.
31. Muller, S., W. H. Miller, Jr., and A. Dejean. 1998. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 92:4308-4316.
32. Ranganathan, R., and E. M. Ross. 1997. PDZ domain proteins: scaffolds for signaling complexes. Curr. Biol. 7:R770-R773.
33. Reineke, E. L., H. Liu, M. Lam, Y. Liu, and H. Y. Kao. 2007. Aberrant association of promyelocytic leukemia protein-retinoic acid receptor-alpha with coactivators contributes to its ability to regulate gene expression. J. Biol. Chem. 282:18584-18596.
34. Ryo, A., Y. C. Liou, G. Wulf, M. Nakamura, S. W. Lee, and K. P. Lu. 2002. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol. Cell. Biol. 22:5281-5295.
35. Ryo, A., M. Nakamura, G. Wulf, Y. C. Liou, and K. P. Lu. 2001. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol. 3:793-801.
36. Ryo, A., F. Suizu, Y. Yoshida, K. Perrem, Y. C. Liou, G. Wulf, R. Rottapel, S. Yamaoka, and K. P. Lu. 2003. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12:1413-1426.
37. Scaglioni, P. P., T. M. Yung, L. F. Cai, H. Erdjument-Bromage, A. J. Kaufman, B. Singh, J. Teruya-Feldstein, P. Tempst, and P. P. Pandolfi. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126:269-283.
38. Schmid, F. X. 1995. Protein folding. Prolyl isomerases join the fold. Curr. Biol. 5:993-994.
39. Shen, M., P. T. Stukenberg, M. W. Kirschner, and K. P. Lu. 1998. The essential mitotic peptidyl-prolyl isomerase Pinl binds and regulates mitosis-specific phosphoproteins. Genes Dev. 12:706-720.
40. Stadler, M., M. K. Chelbi-Alix, M. H. Koken, L. Venturini, C. Lee, A. Saib, F. Quignon, L. Pelicano, M. C. Guillemin, C. Schindler, et al. 1995. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11:2565-2573.
41. Strohmaier, H., C. H. Spruck, P. Kaiser, K. A. Won, O. Sangfelt, and S. I. Reed. 2001. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413:316-322.
42. Takahashi, Y., V. Lallemand-Breitenbach, J. Zhu, and H. de The. 2004. PML nuclear bodies and apoptosis. Oncogene 23:2819-2824.
43. Urist, M., and C. Prives. 2004. The linchpin? Pin1 meets p73. Cancer Cell 5:515-517.
44. van Drogen, F., O. Sangfelt, A. Malyukova, L. Matskova, E. Yeh, A. R. Means, and S. I. Reed. 2006. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol. Cell 23:37-48.
45. Wang, Z. G., L. Delva, M. Gaboli, R. Rivi, M. Giorgio, C. Cordon-Cardo, F. Grosveld, and P. P. Pandolfi. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279:1547-1551.
46. Winkler, K. E., K. I. Swenson, S. Kornbluth, and A. R. Means. 2000. Requirement of the prolyl isomerase Pin1 for the replication checkpoint. Science 287:1644-1647.
47. Wu, R. C., Q. Feng, D. M. Lonard, and B. W. O'Malley. 2007. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 129:1125-1140.
48. Wu, W. S., S. Vallian, E. Seto, W. M. Yang, D. Edmondson, S. Roth, and K. S. Chang. 2001. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol. Cell. Biol. 21:2259-2268.
49. Wulf, G., G. Finn, F. Suizu, and K. P. Lu. 2005. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat. Cell Biol. 7:435-441.
50. Wulf, G., P. Garg, Y. C. Liou, D. Iglehart, and K. P. Lu. 2004. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J. 23:3397-3407.
51. Wulf, G., A. Ryo, Y. C. Liou, and K. P. Lu. 2003. The prolyl isomerase Pin1 in breast development and cancer. Breast Cancer Res. 5:76-82.
52. Xu, Z. X., R. X. Zhao, T. Ding, T. T. Tran, W. Zhang, P. P. Pandolfi, and K. S. Chang. 2004. Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression. J. Biol. Chem. 279:1838-1844.
53. Yaffe, M. B., M. Schutkowski, M. Shen, X. Z. Zhou, P. T. Stukenberg, J. U. Rahfeld, J. Xu, J. Kuang, M. W. Kirschner, G. Fischer, L. C. Cantley, and K. P. Lu. 1997. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 278:1957-1960.
54. Yeh, E., M. Cunningham, H. Arnold, D. Chasse, T. Monteith, G. Ivaldi, W. C. Hahn, P. T. Stukenberg, S. Shenolikar, T. Uchida, C. M. Counter, J. R. Nevins, A. R. Means, and R. Sears. 2004. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 6:308-318.
55. Yi, P., R. C. Wu, J. Sandquist, J. Wong, S. Y. Tsai, M. J. Tsai, A. R. Means, and B. W. O'Malley. 2005. Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol. Cell. Biol. 25:9687-9699.
56. Zhong, S., S. Muller, S. Ronchetti, P. S. Freemont, A. Dejean, and P. P. Pandolfi. 2000. Role of SUMO-1-modified PML in nuclear body formation. Blood 95:2748-2752.